Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Volinanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.83 |
| ▸ | HTR7 | P34969 | 5/20 | 0.82 |
| ▸ | HTR1D | P28221 | 4/20 | 0.82 |
| ▸ | DRD4 | P21917 | 3/20 | 0.82 |
| ▸ | HRH2 | P25021 | 3/20 | 0.82 |
| ▸ | HTR1B | P28222 | 3/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.82 |
| ▸ | HTR6 | P50406 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Volinanserin SCHEMBL30543449 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL4227186 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL29356737 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL13701277 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL340674 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL29899671 | 0.99 | HTR2B (0.98) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL8008450 | 0.95 | HTR2B (0.90) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL8008033 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL22118439 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL22118455 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1362589-B1 | Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMA INC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-1937265-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1192134-B1 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2007024599-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | WO | claimed |
| EP-1736469-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol | Aventis Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| JP-2002523460-A | — | — | 2002-07-30 | — | — | JP | claimed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-20010041719-A1 | The use of R (+)-alpha- (2,3-Dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl] -4-piper idinemethanol for the treatment of sleep disorders | AVENTISUB II INC. | 2001-11-15 | — | — | US | claimed |
| EP-1140055-A1 | USE OF A 5HT 2A? AND 5HT 2A/C? RECEPTOR ANTAGONIST FOR PREPARING MEDICINES FOR TREATING SNORING AND HIGH RESISTANCE SYNDROME OF UPPER ANATOMICAL AIRWAYS | SANOFI-SYNTHELABO (FR) | 2001-10-10 | — | — | EP | claimed |
| US-6277864-B1 | ADMINISTERING TO PATIENT A SEROTONIN RECEPTOR ANTAGONIST TO TREAT OBSTRUCTIVE SLEEP APNEA WITH FEWER SIDE EFFECTS | AVENTIS PHARMACEUTICALS INC. | 2001-08-21 | — | — | US | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| EP-1105132-A1 | THE USE OF R(+)-G(A)-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | Aventis Pharmaceuticals Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000037068-A1 | USE OF A 5HT2A AND 5HT2A/C RECEPTOR ANTAGONIST FOR PREPARING MEDICINES FOR TREATING SNORING AND HIGH RESISTANCE SYNDROME OF UPPER ANATOMICAL AIRWAYS | SANOFI-SYNTHELABO (FR) | 2000-06-29 | — | — | WO | claimed |
| WO-2000012090-A1 | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | AVENTIS PHARMACEUTICALS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041719-A1 | The use of R (+)-alpha- (2,3-Dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl] -4-piper idinemethanol for the treatment of sleep disorders | PNMT, NAPEPLD, PLD2 | HTR2A 84/4885HTR2B 126/4885HTR2C 40/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HTR2A 1477/4885HTR2B 1312/4885HTR2C 1273/4885 |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | HCRTR2, OPRD1, HCRTR1 | HTR2A 47/4885HTR2B 87/4885HTR2C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.